Your browser doesn't support javascript.
loading
Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
Kaljouw, Sylvia; Jansen, Erik E L; Aitken, Clare A; Harrijvan, Lotte M; Naber, Steffie K; de Kok, Inge M C M.
Afiliação
  • Kaljouw S; Department of Public Health, Erasmus MC University Medical Center, 3015GD, Rotterdam, the Netherlands. Electronic address: s.kaljouw@erasmusmc.nl.
  • Jansen EEL; Department of Public Health, Erasmus MC University Medical Center, 3015GD, Rotterdam, the Netherlands.
  • Aitken CA; Department of Public Health, Erasmus MC University Medical Center, 3015GD, Rotterdam, the Netherlands.
  • Harrijvan LM; Department of Public Health, Erasmus MC University Medical Center, 3015GD, Rotterdam, the Netherlands.
  • Naber SK; Department of Public Health, Erasmus MC University Medical Center, 3015GD, Rotterdam, the Netherlands.
  • de Kok IMCM; Department of Public Health, Erasmus MC University Medical Center, 3015GD, Rotterdam, the Netherlands.
Gynecol Oncol ; 160(3): 713-720, 2021 03.
Article em En | MEDLINE | ID: mdl-33451725
BACKGROUND: With the implementation of primary high-risk human papillomavirus (hrHPV) screening in the Netherlands, an increase was observed in the number of unnecessary referrals (≤Cervical Intraepithelial Neoplasia (CIN) 1) to colposcopy. We aimed to investigate which alternative triage strategies safely reduce unnecessary referrals in HPV-based cervical cancer screening programmes. METHODS: Microsimulation model MISCAN was used to simulate an unvaccinated cohort of ten million 30-year old Dutch women. We calculated unnecessary referrals, cervical cancer incidence, mortality, costs and QALYs for 24 triage strategies. Condition for direct referral (atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), conditional on HPV-genotype 16/18/other high risk (OHR)), type of triage test (cytology alone or combined with hrHPV) and time to triage test (6 or 12 months) was varied. RESULTS: The 24 triage strategies had varying effects on the number of unnecessary referrals ranging from -72% to +35%. Adjusting conditions for referral to 'HPV16/18+ and ASC-US+' and 'HPVOHR+ and HSIL+' and extending the interval between tests to 12 months resulted in a reduction in unnecessary referrals of 40% (incidence +0%, mortality -1%). Reduction in unnecessary referrals without genotyping was achieved by adjusting conditions for direct referral to LSIL (12 months to repeat test) (unnecessary referrals -37%, incidence +2%, mortality +0%). CONCLUSIONS: To reduce the number of unnecessary referrals without increasing incidence and mortality by more than 2% in the Dutch cervical cancer screening programme, genotyping for HPV16 or HPV16/18 should be implemented with 12 months to repeat testing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Colposcopia / Detecção Precoce de Câncer Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Colposcopia / Detecção Precoce de Câncer Idioma: En Ano de publicação: 2021 Tipo de documento: Article